Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Hye Soo Chung  (Chung HS) 5 Articles
Obesity and Metabolic Syndrome
The Association between Z-Score of Log-Transformed A Body Shape Index and Cardiovascular Disease in Korea
Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Shinje Moon, Dong Sun Kim
Diabetes Metab J. 2019;43(5):675-682.   Published online April 26, 2019
DOI: https://doi.org/10.4093/dmj.2018.0169
  • 7,510 View
  • 59 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

In order to overcome the limitations of body mass index (BMI) and waist circumference (WC), the z-score of the log-transformed A Body Shape Index (LBSIZ) has recently been introduced. In this study, we analyzed the relationship between the LBSIZ and cardiovascular disease (CVD) in a Korean representative sample.

Methods

Data were collected from the Korea National Health and Nutrition Examination VI to V. The association between CVD and obesity indices was analyzed using a receiver operating characteristic curve. The cut-off value for the LBSIZ was estimated using the Youden index, and the odds ratio (OR) for CVD was determined via multivariate logistic regression analysis. ORs according to the LBSIZ value were analyzed using restricted cubic spline regression plots.

Results

A total of 31,227 Korean healthy adults were analyzed. Area under the curve (AUC) of LBSIZ against CVD was 0.686 (95% confidence interval [CI], 0.671 to 0.702), which was significantly higher than the AUC of BMI (0.583; 95% CI, 0.567 to 0.599) or WC (0.646; 95% CI, 0.631 to 0.661) (P<0.001). Similar results were observed for stroke and coronary artery diseases. The cut-off value for the LBSIZ was 0.35 (sensitivity, 64.5%; specificity, 64%; OR, 1.29, 95% CI, 1.12 to 1.49). Under restricted cubic spline regression, LBSIZ demonstrated that OR started to increase past the median value.

Conclusion

The findings of this study suggest that the LBSIZ might be more strongly associated with CVD risks compared to BMI or WC. These outcomes would be helpful for CVD risk assessment in clinical settings, especially the cut-off value of the LBSIZ suggested in this study.

Citations

Citations to this article as recorded by  
  • Body Shape Index and Cardiovascular Risk in Individuals With Obesity
    Nazlı Hacıağaoğlu, Can Öner, Hüseyin Çetin, Engin Ersin Şimşek
    Cureus.2022;[Epub]     CrossRef
  • Association between body shape index and risk of mortality in the United States
    Heysoo Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Wankyo Chung, Jae Myung Yu, Chang-Myung Oh, Shinje Moon
    Scientific Reports.2022;[Epub]     CrossRef
  • Utility of the Z-score of log-transformed A Body Shape Index (LBSIZ) in the assessment for sarcopenic obesity and cardiovascular disease risk in the United States
    Wankyo Chung, Jung Hwan Park, Hye Soo Chung, Jae Myung Yu, Dong Sun Kim, Shinje Moon
    Scientific Reports.2019;[Epub]     CrossRef
Clinical Diabetes & Therapeutics
Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies
Juno Kim, Hye Soo Chung, Min-Kyu Choi, Yong Kyun Roh, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Jae Myung Yu, Shinje Moon
Diabetes Metab J. 2019;43(4):447-460.   Published online January 2, 2019
DOI: https://doi.org/10.4093/dmj.2018.0123
  • 5,989 View
  • 96 Download
  • 33 Web of Science
  • 34 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Epidemiological studies have suggested an association between selenium (Se) and diabetes mellitus (DM). However, different studies have reported conflicting results. Therefore, we performed a comprehensive meta-analysis to clarify the impact of Se on DM.

Methods

We searched the PubMed database for studies on the association between Se and DM from inception to June 2018.

Results

Twenty articles evaluating 47,930 participants were included in the analysis. The meta-analysis found that high levels of Se were significantly associated with the presence of DM (pooled odds ratios [ORs], 1.88; 95% confidence interval [CI], 1.44 to 2.45). However, significant heterogeneity was found (I2=82%). Subgroup analyses were performed based on the Se measurement methods used in each study. A significant association was found between high Se levels and the presence of DM in the studies that used blood (OR, 2.17; 95% CI, 1.60 to 2.93; I2=77%), diet (OR, 1.61; 95% CI, 1.10 to 2.36; I2=0%), and urine (OR, 1.49; 95% CI, 1.02 to 2.17; I2=0%) as samples to estimate Se levels, but not in studies on nails (OR, 1.24; 95% CI, 0.52 to 2.98; I2=91%). Because of significant heterogeneity in the studies with blood, we conducted a sensitivity analysis and tested the publication bias. The results were consistent after adjustment based on the sensitivity analysis as well as the trim and fill analysis for publication bias.

Conclusion

This meta-analysis demonstrates that high levels of Se are associated with the presence of DM. Further prospective and randomized controlled trials are warranted to elucidate the link better.

Citations

Citations to this article as recorded by  
  • Increased Expression of PHGDH Under High-Selenium Stress In Vivo
    Qin Wang, Jianrong Wang, Xue Zhang, Yiqun Liu, Feng Han, Xuesong Xiang, Yanbin Guo, Zhen-wu Huang
    Biological Trace Element Research.2024;[Epub]     CrossRef
  • Dosage-effect of selenium supplementation on blood glucose and oxidative stress in type 2 diabetes mellitus and normal mice
    Xiaxia Cai, Zhuo Hu, Mingyuan Zhang, Qinyu Dang, Qian Yang, Xiaoyan Zhao, Yandi Zhu, Yadi Zhang, Yuchen Wei, Haiqin Fang, Huanling Yu
    Journal of Trace Elements in Medicine and Biology.2024; 83: 127410.     CrossRef
  • Biological Activity of Selenium and Its Impact on Human Health
    Giuseppe Genchi, Graziantonio Lauria, Alessia Catalano, Maria Stefania Sinicropi, Alessia Carocci
    International Journal of Molecular Sciences.2023; 24(3): 2633.     CrossRef
  • The Role of Selenium and Manganese in the Formation, Diagnosis and Treatment of Cervical, Endometrial and Ovarian Cancer
    Anna Golara, Mateusz Kozłowski, Paweł Guzik, Sebastian Kwiatkowski, Aneta Cymbaluk-Płoska
    International Journal of Molecular Sciences.2023; 24(13): 10887.     CrossRef
  • Association of Selenium Intake and Selenium Concentrations with Risk of Type 2 Diabetes in Adults: A Narrative Review
    Maha Alharithy, Nora Alafif
    Metabolites.2023; 13(6): 767.     CrossRef
  • Selenium-Containing Organic Fertilizer Application Affects Yield, Quality, and Distribution of Selenium in Wheat
    Peng Chen, Hiba Shaghaleh, Yousef Alhaj Hamoud, Jing Wang, Wenxia Pei, Xianfu Yuan, Jianjian Liu, Cece Qiao, Wenhui Xia, Jianfei Wang
    Life.2023; 13(9): 1849.     CrossRef
  • Selenium Species in Diabetes Mellitus Type 2
    Krystyna Pyrzynska, Aleksandra Sentkowska
    Biological Trace Element Research.2023;[Epub]     CrossRef
  • A Comprehensive Review on Selenium and Its Effects on Human Health and Distribution in Middle Eastern Countries
    Marek Kieliszek, Iqra Bano, Hamed Zare
    Biological Trace Element Research.2022; 200(3): 971.     CrossRef
  • Selenium and clarithromycin loaded PLA-GO composite wound dressings by electrospinning method
    Fatih Ciftci, Sumeyra Ayan, Nilüfer Duygulu, Yasemin Yilmazer, Zeynep Karavelioglu, Meyrem Vehapi, Rabia Cakır Koc, Mustafa Sengor, Hakan Yılmazer, Didem Ozcimen, Oguzhan Gunduz, Cem Bulent Ustundag
    International Journal of Polymeric Materials and Polymeric Biomaterials.2022; 71(12): 898.     CrossRef
  • The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities
    Holger Steinbrenner, Leonidas H. Duntas, Margaret P. Rayman
    Redox Biology.2022; 50: 102236.     CrossRef
  • The Role of Selenium in Pathologies: An Updated Review
    Giulia Barchielli, Antonella Capperucci, Damiano Tanini
    Antioxidants.2022; 11(2): 251.     CrossRef
  • Selenium and Selenoproteins at the Intersection of Type 2 Diabetes and Thyroid Pathophysiology
    Francesca Gorini, Cristina Vassalle
    Antioxidants.2022; 11(6): 1188.     CrossRef
  • Higher selenium was associated with higher risk of diabetes: Consistent evidence from longitudinal and cross-sectional studies based on nail and serum selenium measures
    Ranqi Shao, Liqin Su, Li Li, Jinghuan Wu, Xiaohong He, Deqian Mao, Yibin Cheng, Jingyi Liu, Chen Chen, Yinlong Jin, Sujuan Gao
    Science of The Total Environment.2022; 840: 156618.     CrossRef
  • The Roles and Pathogenesis Mechanisms of a Number of Micronutrients in the Prevention and/or Treatment of Chronic Hepatitis, COVID-19 and Type-2 Diabetes Mellitus
    Khalid M. Sumaily
    Nutrients.2022; 14(13): 2632.     CrossRef
  • Associations between Circulating SELENOP Level and Disorders of Glucose and Lipid Metabolism: A Meta-Analysis
    Ruirui Yu, Zhoutian Wang, Miaomiao Ma, Ping Xu, Longjian Liu, Alexey A. Tinkov, Xin Gen Lei, Ji-Chang Zhou
    Antioxidants.2022; 11(7): 1263.     CrossRef
  • Cross-Sectional Association of Blood Selenium with Glycemic Biomarkers among U.S. Adults with Normoglycemia in the National Health and Nutrition Examination Survey 2013–2016
    Jingli Yang, En Chen, Cheukling Choi, Kayue Chan, Qinghua Yang, Juwel Rana, Bo Yang, Chuiguo Huang, Aimin Yang, Kenneth Lo
    Nutrients.2022; 14(19): 3972.     CrossRef
  • Plasma and vitreous selenium concentrations in patients with type 2 diabetes and diabetic retinopathy
    Chunmiao Wang, Ruijin Ran, Xin Jin, Xiaohong Zhu
    Medicine.2022; 101(39): e30877.     CrossRef
  • Emerging roles of selenium on metabolism and type 2 diabetes
    Jiuxiang Zhao, Hong Zou, Yanling Huo, Xiaoyi Wei, Yu Li
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Selenium: Role in preserving and improving health and preventing disease
    Goran Belojević
    Galenika Medical Journal.2022; 1(4): 90.     CrossRef
  • A comprehensive review on the neuropathophysiology of selenium
    Mohammad Naderi, Pankaj Puar, Mahtab Zonouzi-Marand, Douglas P. Chivers, Som Niyogi, Raymond W.M. Kwong
    Science of The Total Environment.2021; 767: 144329.     CrossRef
  • Dietary selenium intake and risk of hospitalization for type 2 diabetes in the Moli-sani study cohort
    Marco Vinceti, Marialaura Bonaccio, Tommaso Filippini, Simona Costanzo, Lauren A. Wise, Augusto Di Castelnuovo, Emilia Ruggiero, Mariarosaria Persichillo, Chiara Cerletti, Maria Benedetta Donati, Giovanni de Gaetano, Licia Iacoviello
    Nutrition, Metabolism and Cardiovascular Diseases.2021; 31(6): 1738.     CrossRef
  • A systematic review and dose-response meta-analysis of exposure to environmental selenium and the risk of type 2 diabetes in nonexperimental studies
    Marco Vinceti, Tommaso Filippini, Lauren A. Wise, Kenneth J. Rothman
    Environmental Research.2021; 197: 111210.     CrossRef
  • Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity
    Dominika Radomska, Robert Czarnomysy, Dominik Radomski, Anna Bielawska, Krzysztof Bielawski
    Nutrients.2021; 13(5): 1649.     CrossRef
  • Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases
    Rannapaula Lawrynhuk Urbano Ferreira, Karine Cavalcanti Maurício Sena-Evangelista, Eduardo Pereira de Azevedo, Francisco Irochima Pinheiro, Ricardo Ney Cobucci, Lucia Fatima Campos Pedrosa
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization?
    Jia-Yue Duan, Xiao Lin, Feng Xu, Su-Kang Shan, Bei Guo, Fu-Xing-Zi Li, Yi Wang, Ming-Hui Zheng, Qiu-Shuang Xu, Li-Min Lei, Wen-Lu Ou-Yang, Yun-Yun Wu, Ke-Xin Tang, Ling-Qing Yuan
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Selenium Intake and Glycemic Control in Young Adults With Normal-Weight Obesity Syndrome
    Acsa de Castro Santos, Anna Flavia Ferreira Passos, Luciana Carla Holzbach, Cristiane Cominetti
    Frontiers in Nutrition.2021;[Epub]     CrossRef
  • Development and Therapeutic Potential of Selenazo Compounds
    Ana Carolina Ruberte, Carmen Sanmartin, Carlos Aydillo, Arun K. Sharma, Daniel Plano
    Journal of Medicinal Chemistry.2020; 63(4): 1473.     CrossRef
  • Selenium in thyroid disorders — essential knowledge for clinicians
    Kristian Hillert Winther, Margaret Philomena Rayman, Steen Joop Bonnema, Laszlo Hegedüs
    Nature Reviews Endocrinology.2020; 16(3): 165.     CrossRef
  • Safety of selenium‐enriched biomass of Yarrowia lipolytica as a novel food pursuant to Regulation (EU) 2015/2283
    Dominique Turck, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch‐Ernst, John Kearney, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri, Marc
    EFSA Journal.2020;[Epub]     CrossRef
  • The Association of Circulating Selenium Concentrations with Diabetes Mellitus


    Xiao-Long Liao, Zhong-Hua Wang, Xiu-Na Liang, Jun Liang, Xue-Biao Wei, Shou-Hong Wang, Wei-Xin Guo
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4755.     CrossRef
  • A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Hashimoto’s Thyroiditis
    Kristian Hillert Winther, Enrico Papini, Roberto Attanasio, Roberto Negro, Laszlo Hegedüs
    European Thyroid Journal.2020; 9(2): 99.     CrossRef
  • Systems Biology of Selenium and Complex Disease
    Huimin Ying, Yan Zhang
    Biological Trace Element Research.2019; 192(1): 38.     CrossRef
  • Effectiveness and safety of selenium supplementation for type 2 diabetes mellitus in adults: a systematic review of randomised controlled trials
    A. Stróżyk, Z. Osica, J. D. Przybylak, M. Kołodziej, B. M. Zalewski, B. Mrozikiewicz‐Rakowska, H. Szajewska
    Journal of Human Nutrition and Dietetics.2019; 32(5): 635.     CrossRef
  • Selenium and Health: An Update on the Situation in the Middle East and North Africa
    Sohayla A. Z. Ibrahim, Abdelhamid Kerkadi, Abdelali Agouni
    Nutrients.2019; 11(7): 1457.     CrossRef
Obesity and Metabolic Syndrome
Proportion and Characteristics of the Subjects with Low Muscle Mass and Abdominal Obesity among the Newly Diagnosed and Drug-Naïve Type 2 Diabetes Mellitus Patients
Jung A Kim, Soon Young Hwang, Hye Soo Chung, Nam Hoon Kim, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
Diabetes Metab J. 2019;43(1):105-113.   Published online September 28, 2018
DOI: https://doi.org/10.4093/dmj.2018.0036
  • 4,626 View
  • 68 Download
  • 13 Web of Science
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Sarcopenic obesity (SO) is a serious public health concern, few studies have examined the clinical implications of SO in newly-diagnosed type 2 diabetes mellitus (T2DM) patients. We evaluated the prevalence of the newly diagnosed, drug-naïve T2DM patients with low muscle mass with abdominal obesity and its association with insulin resistance and other diabetic complications.

Methods

We classified 233 drug-naïve T2DM subjects into four groups according to abdominal obesity (waist circumference ≥90 cm in men and ≥85 cm in women) and low muscle mass status (appendicular skeletal muscle <7.0 kg/m2 for men and <5.4 kg/m2 for women).

Results

The proportion of the subjects with low muscle mass and abdominal obesity among the newly diagnosed, drug-naïve T2DM patients was 8.2%. Homeostasis model assessment of insulin resistance (HOMA-IR) increased linearly according to body composition group from normal to abdominal obesity to both low muscle mass and abdominal obesity. The multiple logistic regression analysis indicated that subjects with low muscle mass and abdominal obesity (odds ratio [OR], 9.39; 95% confidence interval [CI], 2.41 to 36.56) showed a higher risk for insulin resistance, defined as HOMA-IR ≥3, than those with abdominal obesity (OR, 5.36; 95% CI, 2.46 to 11.69), even after adjusting for other covariates. However, there were no differences in lipid profiles, microalbuminuria, or various surrogate markers for atherosclerosis among the four groups.

Conclusion

Subjects with both low muscle mass and abdominal obesity had a higher risk of insulin resistance than those with low muscle mass or abdominal obesity only.

Citations

Citations to this article as recorded by  
  • Clinical observation on acupuncture for 80 patients with abdominal obesity in Germany: based on the theory of unblocking and regulating the Belt Vessel
    Yuanyuan Li, Hang Xiong, Shuhui Ma, Jingzhang Dai
    Journal of Acupuncture and Tuina Science.2023; 21(2): 137.     CrossRef
  • Waist circumference and end‐stage renal disease based on glycaemic status: National Health Insurance Service data 2009–2018
    Yun Kyung Cho, Ji Hye Huh, Shinje Moon, Yoon Jung Kim, Yang‐Hyun Kim, Kyung‐do Han, Jun Goo Kang, Seong Jin Lee, Sung‐Hee Ihm
    Journal of Cachexia, Sarcopenia and Muscle.2023; 14(1): 585.     CrossRef
  • Incidence of sarcopenic obesity in older patients with diabetes and association between sarcopenic obesity and higher-level functional capacity: evaluation based on a consensus statement
    Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Kentaro Azuma, Kazuya Murata
    Endocrine Journal.2023; 70(6): 591.     CrossRef
  • A Novel Anthropometric Parameter, Weight-Adjusted Waist Index Represents Sarcopenic Obesity in Newly Diagnosed Type 2 Diabetes Mellitus
    Min Jeong Park, Soon Young Hwang, Nam Hoon Kim, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Journal of Obesity & Metabolic Syndrome.2023; 32(2): 130.     CrossRef
  • Prevalence of sarcopenic obesity in patients with diabetes and adverse outcomes: A systematic review and meta-analysis
    Yuan-yuan Zhou, Jin-feng Wang, Qian Yao, Qiu-feng Jian, Zhi-peng Luo
    Clinical Nutrition ESPEN.2023; 58: 128.     CrossRef
  • The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
    Menggege Liu, Qing Zhang, Juan Liu, Huiling Bai, Ping Yang, Xinhua Ye, Xiaoqing Yuan
    Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 4169.     CrossRef
  • Sarcopenic Obesity with Normal Body Size May Have Higher Insulin Resistance in Elderly Patients with Type 2 Diabetes Mellitus
    Tingting Han, Ting Yuan, Xinyue Liang, Ningxin Chen, Jia Song, Xin Zhao, Yurong Weng, Yaomin Hu
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1197.     CrossRef
  • Relationship between Visceral Adipose Index, Lipid Accumulation Product and Type 2 Diabetes Mellitus
    停停 陈
    Advances in Clinical Medicine.2022; 12(04): 3350.     CrossRef
  • Assessment of the relationship between prediabetes and low skeletal mass based on blood creatinine level
    S. I. Ibragimova, G. O. Nuskabayeva, Z. N. Shalkharova, K. Zh. Sadykova, G. A. Junusbekova, M. Oran
    Diabetes mellitus.2022; 25(3): 226.     CrossRef
  • Changes in body composition and low blood urea nitrogen level related to an increase in the prevalence of fatty liver over 20 years: A cross‐sectional study
    Yasushi Imamura, Seiichi Mawatari, Kohei Oda, Kotaro Kumagai, Yasunari Hiramine, Akiko Saishoji, Atsuko Kakihara, Mai Nakahara, Manei Oku, Kaori Hosoyamada, Shuji Kanmura, Akihiro Moriuchi, Hironori Miyahara, Akio ido
    Hepatology Research.2021; 51(5): 570.     CrossRef
  • Body Composition and Diabetes
    Hye Jin Yoo
    The Journal of Korean Diabetes.2021; 22(4): 238.     CrossRef
  • Reduced Skeletal Muscle Volume and Increased Skeletal Muscle Fat Deposition Characterize Diabetes in Individuals after Pancreatitis: A Magnetic Resonance Imaging Study
    Andre E. Modesto, Juyeon Ko, Charlotte E. Stuart, Sakina H. Bharmal, Jaelim Cho, Maxim S. Petrov
    Diseases.2020; 8(3): 25.     CrossRef
  • Low alanine aminotransferase levels predict low muscle strength in older patients with diabetes: A nationwide cross‐sectional study in Korea
    Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Geriatrics & Gerontology International.2020; 20(4): 271.     CrossRef
  • Association between sarcopenic obesity and higher risk of type 2 diabetes in adults: A systematic review and meta-analysis
    Dima Khadra, Leila Itani, Hana Tannir, Dima Kreidieh, Dana El Masri, Marwan El Ghoch
    World Journal of Diabetes.2019; 10(5): 311.     CrossRef
Smaller Mean LDL Particle Size and Higher Proportion of Small Dense LDL in Korean Type 2 Diabetic Patients
Sunghwan Suh, Hyung-Doo Park, Se Won Kim, Ji Cheol Bae, Alice Hyun-Kyung Tan, Hye Soo Chung, Kyu Yeon Hur, Jae Hyeon Kim, Kwang-Won Kim, Moon-Kyu Lee
Diabetes Metab J. 2011;35(5):536-542.   Published online October 31, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.5.536
  • 4,342 View
  • 39 Download
  • 13 Crossref
AbstractAbstract PDFPubReader   
Background

Small dense low density lipoprotein (sdLDL) has recently emerged as an important risk factor of coronary heart disease.

Methods

The mean LDL particle size was measured in 203 patients with type 2 diabetes mellitus (T2DM) and 212 matched subjects without diabetes using polyacrylamide tube gel electrophoresis. Major vascular complications were defined as stroke, angiographically-documented coronary artery disease or a myocardial infarction. Peripheral vascular stenosis, carotid artery stenosis (≥50% in diameter) or carotid artery plaque were considered minor vascular complications. Overall vascular complications included both major and minor vascular complications.

Results

Diabetic patients had significantly smaller mean-LDL particle size (26.32 nm vs. 26.49 nm) and a higher percentage of sdLDL to total LDL compared to those of subjects without diabetes (21.39% vs. 6.34%). The independent predictors of sdLDL in this study were serum triglyceride level and body mass index (odds ratio [OR], 1.020 with P<0.001 and OR 1.152 with P<0.027, respectively). However, no significant correlations were found between sdLDL and major vascular complications (P=0.342), minor vascular complications (P=0.573) or overall vascular complications (P=0.262) in diabetic subjects.

Conclusion

Diabetic patients had a smaller mean-LDL particle size and higher proportion of sdLDL compared to those of subjects without diabetes. Obese diabetic patients with hypertriglyceridemia have an increased risk for atherogenic small dense LDL. However, we could not verify an association between LDL particle size and vascular complications in this study.

Citations

Citations to this article as recorded by  
  • Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
    Hyun‐Ki Kim, Jinyoung Hong, Sunyoung Ahn, Woochang Lee, Sail Chun, Won‐Ki Min
    Journal of Clinical Laboratory Analysis.2023;[Epub]     CrossRef
  • The association of apolipoprotein in the risk of ST-elevation myocardial infarction in patients with documented coronary artery disease
    Astuti Giantini, Nur Gifarani Pratiwi, Renan Sukmawan, Joedo Prihartono, Suzanna Immanuel, Merci Monica Pasaribu, Sri Suryo Adiyanti, Yusuf Bahasoan
    International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 18: 200194.     CrossRef
  • Atherogenic Index of Plasma and Its Association with Risk Factors of Coronary Artery Disease and Nutrient Intake in Korean Adult Men: The 2013–2014 KNHANES
    Hye Ran Shin, SuJin Song, Jin Ah Cho, Sun Yung Ly
    Nutrients.2022; 14(5): 1071.     CrossRef
  • The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes
    Kuo Zhou, Zheng Qin, Jinfan Tian, Kongyong Cui, Yunfeng Yan, Shuzheng Lyu
    Angiology.2021; 72(10): 934.     CrossRef
  • Direct bilirubin is associated with low-density lipoprotein subfractions and particle size in overweight and centrally obese women
    Y.-J. Kwon, H.-S. Lee, J.-W. Lee
    Nutrition, Metabolism and Cardiovascular Diseases.2018; 28(10): 1021.     CrossRef
  • Correlation between Cholesterol, Triglycerides, Calculated, and Measured Lipoproteins: Whether Calculated Small Density Lipoprotein Fraction Predicts Cardiovascular Risks
    Sikandar Hayat Khan, Nadeem Fazal, Athar Abbas Gilani Shah, Syed Mohsin Manzoor, Naveed Asif, Aamir Ijaz, Najmusaqib Khan Niazi, Muhammad Yasir
    Journal of Lipids.2017; 2017: 1.     CrossRef
  • Effects of Small Dense LDL in Diabetic Nephropathy in Females with Type 2 Diabetes Mellitus
    Seongyul Ryu, Youngwoo Kim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Hyun Baek, Ki-Ho Song, Kyung-Jin Yun
    Journal of Lipid and Atherosclerosis.2016; 5(1): 11.     CrossRef
  • Prepregnancy Adverse Lipid Profile and Subsequent Risk of Gestational Diabetes
    Emily S. Han, Ronald M. Krauss, Fei Xu, Sneha B. Sridhar, Assiamira Ferrara, Charles P. Quesenberry, Monique M. Hedderson
    The Journal of Clinical Endocrinology & Metabolism.2016; 101(7): 2721.     CrossRef
  • Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus
    Xiao-Wei Zhu, Fei-Yan Deng, Shu-Feng Lei
    Primary Care Diabetes.2015; 9(1): 60.     CrossRef
  • Higher levels of small dense low‐density lipoprotein (LDL) are associated with cardiac autonomic neuropathy in patients with Type 2 diabetes
    E.‐H. Jang, Y.‐M. Park, J. Hur, M.‐K. Kim, S.‐H. Ko, K.‐H. Baek, K.‐H. Song, K.‐W. Lee, H.‐S. Kwon
    Diabetic Medicine.2013; 30(6): 694.     CrossRef
  • Sleep Status and Low-Density Lipoprotein Particle Size in a General Japanese Female Population: The Mima Study
    Kazuhiko Kotani, Kokoro Tsuzaki, Shinji Fujiwara, Naoki Sakane
    Medical Principles and Practice.2013; 22(5): 510.     CrossRef
  • Serum small-dense LDL abnormalities in chronic renal disease patients
    M. Chu, A. Y. M. Wang, I. H. S. Chan, S. H. Chui, C. W. K. Lam
    British Journal of Biomedical Science.2012; 69(3): 99.     CrossRef
  • Small Dense Low-density Lipoprotein and Cardiovascular Disease
    Sunghwan Suh, Moon-Kyu Lee
    Journal of Lipid and Atherosclerosis.2012; 1(1): 1.     CrossRef
Efficacy of Sitagliptin When Added to Ongoing Therapy in Korean Subjects with Type 2 Diabetes Mellitus
Hye Soo Chung, Moon-Kyu Lee
Diabetes Metab J. 2011;35(4):411-417.   Published online August 31, 2011
DOI: https://doi.org/10.4093/dmj.2011.35.4.411
  • 3,225 View
  • 69 Download
  • 12 Crossref
AbstractAbstract PDFPubReader   
Background

To evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 diabetes mellitus during a 14-week treatment period.

Methods

Our study design involved the addition of 100 mg sitagliptin once-daily to three ongoing combination therapy regimens and changing from glimepiride and metformin to sitagliptin and metformin.

Results

The addition of sitagliptin 100 mg/day produced a statistically significant reduction in mean HbA1c level (mean HbA1c reduction of 0.99±0.85%, P<0.01). In the group taking a combination of sitagliptin and metformin (n=143, initial mean HbA1c level=7.48%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 0.72±0.76% (P<0.01), 47±65 mg/dL (P<0.01), and 15±44 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, and metformin (n=125, initial mean HbA1c level=8.42%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.09±0.86% (P<0.01), 62±64 mg/dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, metformin, and α-glucosidase inhibitor (n=63, initial mean HbA1c level=9.19%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), and 35±51 mg/dL (P<0.01), respectively. In the group that had previous hypoglycemic events and that changed from glimepiride to sitagliptin, HbA1c level did not change but fasting glucose increased significantly (14±29 mg/dL, P<0.01).

Conclusion

Sitagliptin combination therapy for 14 weeks significantly improved glycemic control and was well-tolerated in Korean subjects with type 2 diabetes mellitus.

Citations

Citations to this article as recorded by  
  • Impact of Treviamet® & Treviamet XR® on quality of life besides glycemic control in type 2 DM patients
    Asima Khan, Muhammad Adnan Kanpurwala, Riasat Ali Khan, Najum F. Mahmudi, Verumal Lohano, Shakeel Ahmed, Majid Khan, Fareed Uddin, Syed Mohammad Ali, Maliha Saghir, Syed Hussain Baqar Abidi, Jahanzeb Kamal
    BMC Endocrine Disorders.2023;[Epub]     CrossRef
  • Efficacy and safety of sitagliptin/metformin fixed‐dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double‐blind study
    Sang Soo Kim, In Joo Kim, Kwang Jae Lee, Jeong Hyun Park, Young Il Kim, Young Sil Lee, Sung Chang Chung, Sang Jin Lee
    Journal of Diabetes.2017; 9(4): 412.     CrossRef
  • Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
    Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha
    Endocrinology and Metabolism.2015; 30(1): 84.     CrossRef
  • Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis
    JM. Amate, T. Lopez‐Cuadrado, N. Almendro, C. Bouza, Z. Saz‐Parkinson, R. Rivas‐Ruiz, J. Gonzalez‐Canudas
    International Journal of Clinical Practice.2015; 69(3): 292.     CrossRef
  • Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
    Ye An Kim, Won Sang Yoo, Eun Shil Hong, Eu Jeong Ku, Kyeong Seon Park, Soo Lim, Young Min Cho, Kyong Soo Park, Hak Chul Jang, Sung Hee Choi
    Diabetes & Metabolism Journal.2015; 39(6): 489.     CrossRef
  • Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments
    Katsunori Suzuki, Yurie Mistuma, Takaaki Sato, Mariko Hatta
    International Journal of Clinical Medicine.2015; 06(09): 672.     CrossRef
  • Short‐ and long‐term effect of sitagliptin after near normalization of glycemic control with insulin in poorly controlled Japanese type 2 diabetic patients
    Keiko Fujisawa, Tetsuyuki Yasuda, Hideaki Kaneto, Naoto Katakami, Mayumi Tsuji, Fumiyo Kubo, Shugo Sasaki, Kazuyuki Miyashita, Toyoko Naka, Ryuuichi Kasami, Akio Kuroda, Munehide Matsuhisa, Iichiro Shimomura
    Journal of Diabetes Investigation.2014; 5(5): 548.     CrossRef
  • Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
    Chun-Jun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu, De-Min Yu
    Diabetology & Metabolic Syndrome.2014;[Epub]     CrossRef
  • Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
    Sun Ok Song, Kwang Joon Kim, Byung‐Wan Lee, Eun Seok Kang, Bong Soo Cha, Hyun Chul Lee
    Journal of Diabetes Investigation.2014; 5(5): 554.     CrossRef
  • Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy
    Keiji Yoshioka, Haruhiko Isotani, Shin-ichiro Ohashi, Minoru Imamura
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2013; 7(1): 32.     CrossRef
  • Glimepiride Strongly Enhances the Glucose-Lowering Effect in Triple Oral Antidiabetes Therapy with Sitagliptin and Metformin for Japanese Patients with Type 2 Diabetes Mellitus
    Keiko Arai, Hajime Maeda, Sin-ichiro Sirabe, Ritsuko Yamamoto, Mikio Yamauchi, Tetsuyuki Hirao, Setsuko Hirao, Koichi Hirao
    Diabetes Technology & Therapeutics.2013; 15(4): 335.     CrossRef
  • Efficacy of sitagliptin on blood glucose fluctuation in Japanese type 2 diabetic patients with basal-supported oral therapy
    Mitsuyoshi Takahara, Toshihiko Shiraiwa, Hideaki Kaneto, Naoto Katakami, Taka-aki Matsuoka, Iichiro Shimomura
    Endocrine Journal.2012; 59(12): 1131.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal